XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
REVENUES    
Total revenues $ 1,607,170 $ 722,029
EXPENSES    
Cost of product sales 1,264,828 828,848
General and administrative 1,714,434 2,898,751
Research and development 2,121,551 1,864,745
Sales and marketing 199,114 138,323
Total expenses 5,299,927 5,730,667
LOSS FROM OPERATIONS (3,692,757) (5,008,638)
OTHER EXPENSE (INCOME), NET    
Gain on change in fair value of warrant liabilities (1,038,673) (683,242)
Interest expense (income), net 544,236 (6,309)
Loss on voluntary conversion of convertible debt 1,077,287
Other income, net (4,881) (36)
Loss on fixed asset disposal 300
Total other expense (income), net 578,269 (689,587)
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES (4,271,026) (4,319,051)
(BENEFIT) PROVISION FOR INCOME TAXES (163,777) 736
Net loss (4,107,249) (4,319,787)
Net loss attributable to noncontrolling interest (261,028)
Net loss attributable to Qualigen Therapeutics, Inc. $ (3,846,221) $ (4,319,787)
Net loss per common share, basic and diluted $ (0.78) $ (1.22)
Weighted—average number of shares outstanding, basic and diluted 4,959,122 3,529,405
Other comprehensive loss, net of tax    
Foreign currency translation adjustment $ 119,723
Other comprehensive loss (3,987,526) (4,319,787)
Comprehensive loss attributable to noncontrolling interest (261,028)
Comprehensive loss attributable to Qualigen Therapeutics, Inc. (3,726,498) (4,319,787)
Net Product Sales [Member]    
REVENUES    
Total revenues $ 1,607,170 $ 722,029